Baxdrostat bioavailability and bioequivalence study

Exclusion Criteria

• 1. Actively participating in an experimental therapy study; received experimental therapy with a small molecule other than CIN-107 within 30 days of the first dose of study drug, or 5 halflives, whichever is longer; or received experimental therapy with a large molecule within 90 days of the first dose of study drug, or 5 half-lives, whichever is longer.
• 2. A personal or family history of long QT syndrome, Torsades de Pointes, or other complex ventricular arrhythmias, or family history of sudden death.
• 3. History of, or current, clinically significant arrhythmias as judged by the Investigator,
• including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, sinus node
• dysfunction, or clinically significant heart block. Subjects with minor forms of ectopy (eg,
• premature atrial contractions) are not necessarily excluded.
• 4. Prolonged QTcF (>450 msec).
• 5. Seated blood pressure higher than 150/90 mmHg or lower than 90/50.
• 6. Resting heart rate higher than 100 bpm or lower than 50 bpm.
• 7. Temperature (T) greater than 37.6 C (99.68 F), measured orally, and respiration rate less than 12 or greater than 20 breaths/minute.
• 8. Postural tachycardia (i.e. >30 bpm upon standing) or orthostatic hypotension (i.e., a fall in systolic blood pressure (SBP) of ≥20 mm Hg or diastolic blood pressure (DBP) of ≥ 10 mm Hg when a person assumes a standing position).
• 9. Serum potassium > upper limit of normal of the reference range (ULN) and serum
• sodium < lower limit of normal of the reference range (LLN).
• 10. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values > 1.2 ULN.
• 11. Positive for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV)
• antibody, or Hepatitis B surface antigen (HBsAg).
• 12. Any other clinical laboratory values which are meaningfully outside of normal limits (based on laboratory normal range) in the opinion of the Investigator.
• 13. A known history of porphyria, myopathy, or an active liver disease.
• 14. Evidence or history of any clinically significant immunologic, hematologic, renal,
• endocrine, pulmonary, gastrointestinal, cardiovascular, musculoskeletal, hepatic,
• psychiatric, neurologic, or allergic disease (including clinically significant or multiple drug
• allergies); surgical conditions; cancer (with the exception of basal or squamous cell
• carcinoma of the skin and cancer that resolved or has been in remission for >5 years prior to Screening); or any condition that, in the Investigator's opinion, may confound study
• procedures or results, impact subject safety, or interfere with the absorption, distribution,
• metabolism, or excretion of the study drug (appendectomy allowed, cholecystectomy
• prohibited).
• 15. Use of any prescription medications (including topicals) or over-the-counter medications (other than occasional use of acetaminophen or nonsteroidal anti-inflammatory drugs, such as ibuprofen or naproxen, according to the package insert); herbal supplements; dietary supplements; or nutraceuticals within 14 days prior to the first dose of study drug, or 5 halflives, whichever is longer, or an unwillingness to refrain from these medications through discharge from the clinical unit. Note: Use of over-the-counter topical medications may be permitted in consultation with the Sponsor. In addition, medications for which 5 half-lives exceeds 14 days must be discussed with and approved by the Sponsor prior to subject enrollment.
• 16. Corticosteroid use (systemic or extensive topical) within 3 months prior to dosing.
• 17. Positive drug or alcohol test result or a history of alcoholism or drug abuse within 2 years prior to the first dose of study drug as defined by the Diagnostic and Statistical Manual (DSM) of Mental Disorders, 4th Edition: DSM-IV.
• 18. Typical consumption of ≥14 alcoholic drinks weekly. Note: 1 drink of alcohol is equivalent to ½ pint of beer (285 mL), 1 glass of spirits (25 mL), or 1 glass of wine (125 mL).
• 19. History of or evidence of illicit drug use within the past 2 years.
• 20. Surgical procedures within 4 weeks of check-in or planned elective surgery during the study period.
• 21. Any illness during the 4 weeks before check-in, unless deemed not clinically significant by the Investigator.
• 22. Known allergy to any ingredient of the study drug. Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
• 23. Inadequate venous access.
• 24. Currently undergoing treatment with weight loss medication or prior weight loss surgery (e.g., gastric bypass surgery).
• 25. Pregnant, breastfeeding, or planning to become pregnant during the study.
• 26. Considered by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluation, to be unsuitable for any other reason that may either place the subject at increased risk during participation or interfere with the
• interpretation of the study outcomes.